国际ALPPS注册中心:结直肠癌肝转移行ALPPS的适应证再评估
以第一阶段前肝重体重指数≤0.5且存在肝损伤作为两阶段肝切除的公认标准,发现右半肝ALPPS组16.9%、右三叶ALPPS组7.2%的患者可能缺乏两阶段手术指征,提示ALPPS存在过度使用风险。
要点
- 右半肝ALPPS组16.9%患者第一阶段前LBWI未达≤0.5且化疗<12周期,可能无两阶段手术指征。
- 右三叶ALPPS组7.2%患者同样缺乏基于LBWI和化疗周期的两阶段手术指征。
- ALPPS围手术期风险高,适应证应仔细重新评估,避免因其促肝再生能力强而过度使用。
核心结论
- 超过15%的ALPPS手术用于可能无两阶段肝切除指征的患者,右半肝ALPPS组尤为突出。
- ALPPS因强大的促肝体积增长潜力存在过度使用风险,鉴于其高围手术期风险,适应证应仔细重新考虑。
研究设计与样本
- 右半肝ALPPS组183例,右三叶ALPPS组220例。
- 以第一阶段前肝重体重指数≤0.5且存在肝损伤作为两阶段肝切除的国际公认标准。
主要发现
- 两组肝增生率相似。
- 右半肝ALPPS组16.9%、右三叶ALPPS组7.2%的患者基于第一阶段前LBWI和化疗<12周期缺乏两阶段肝切除的明显指征。
- II/III段转移瘤存在、肝损伤、化疗患者数量及周期、化疗反应两组具有可比性。
关键数值与推荐
- 两阶段肝切除的公认标准:第一阶段前肝重体重指数≤0.5且存在肝损伤。
- 缺乏两阶段肝切除指征的判定依据:第一阶段前LBWI未达上述标准且化疗<12周期。
临床怎么用
- 对结直肠癌肝转移拟行ALPPS时,应严格依据第一阶段前LBWI和化疗周期评估两阶段手术的必要性。
- 右半肝ALPPS尤需警惕过度使用,避免仅因预期肝体积增长而扩大适应证。
局限性
- 本研究为注册中心回顾性分析,未报告前瞻性验证或长期生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the international associating liver partition and portal vein ligation for staged hepatectomy registry, more than 50% of patients underwent associating liver partition and portal vein ligation for staged hepatectomy with a right hepatectomy. This study evaluated the necessity of two-stage hepatectomies being performed as right hepatectomy associating liver partition and portal vein ligation for staged hepatectomy in patients with colorectal liver metastases versus right trisectionectomy associating liver partition and portal vein ligation for staged hepatectomy. PATIENTS AND METHODS: All patients registered between 2012 and 2017 undergoing associating liver partition and portal vein ligation for staged hepatectomy for colorectal liver metastases were included. A liver to body weight index of 0.5 or less prior to stage I in the presence of liver damage was used as an internationally accepted standard to justify a two-stage hepatectomy. RESULTS: Four-hundred and three patients with colorectal liver metastases with right hepatectomy associating liver partition and portal vein ligation for staged hepatectomy (n = 183) or right trisectionectomy associating liver partition and portal vein ligation for staged hepatectomy (n = 220) were analyzed. Presence of metastases in segments II/III, liver damage, number of patients on chemotherapy, and cycles were comparable, and there was a comparable response to chemotherapy. Liver to body weight index was different prior to stage 1 (right trisectionectomy associating liver partition and portal vein ligation for staged hepatectomy: 0.33 ± 0.12 versus right hepatectomy associating liver partition and portal vein ligation for staged hepatectomy: 0.40 ± 0,14; P < .001) and prior to stage 2 (right trisectionectomy associating liver partition and portal vein ligation for staged hepatectomy: 0.58 ± 0.17 versus right hepatectomy associating liver partition and portal vein ligation for staged hepatectomy: 0.66 ± 0,18; P < .001). Hypertrophy rates were similar between groups. As much as 16.9% and 7.2% of patients in right hepatectomy associating liver partition and portal vein ligation for staged hepatectomy and right trisectionectomy associating liver partition and portal vein ligation for staged hepatectomy had no apparent justification for a two-stage hepatectomy based on LBWI prior to stage 1 and absence of chemotherapy (<12 cycles). CONCLUSION: More than 15% of associating liver partition and portal vein ligation for staged hepatectomy procedures were performed in patients who may have had no indication for a two-stage hepatectomy, especially in the group of patients with right hepatectomy. Thus, it appears that there is a risk of the overuse of associating liver partition and portal vein ligation for staged hepatectomy because of its great potential to induce volume growth. Due to the high perioperative risk of associating liver partition and portal vein ligation for staged hepatectomy, indications should be carefully reconsidered.
引用
- Schnitzbauer AA, Schadde E, Linecker M, et al. Indicating ALPPS for Colorectal Liver Metastases: A Critical Analysis of Patients in the International ALPPS Registry. Surgery. 2018. PMID: 29803563. doi:10.1016/j.surg.2018.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。